Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Excreted antibiotics become potential sources of antibiotic resistant genes

When an antibiotic is consumed, researchers have learned that up to 90 percent passes through a body without metabolizing. This means the drugs can leave the body almost intact through normal bodily functions.

9 Dec 2010

St. Luke's Episcopal Hospital, UH College of Pharmacy earn national 'best practices' award

With antibiotic resistance on the rise worldwide, health care professionals are continually seeking to optimize how they combat drug-resistant infections.

8 Dec 2010

Scientists work together to wipe out some of the most lethal diseases

Scientists at Seattle Biomedical Research Institute and Northwestern University Feinberg School of Medicine have reached a major milestone in the effort to wipe out some of the most lethal diseases on the planet. As leaders of two large structural genomics centers, they've experimentally determined 500 three-dimensional protein structures from a number of bacterial and protozoan pathogens, which could potentially lead to new drugs, vaccines and diagnostics to combat deadly infectious diseases.

8 Dec 2010

Idis to manage ViroPharma's named patient program

ViroPharma Incorporated and Idis, the global leader in developing long-term strategic solutions to therapeutic access, today announced that the two companies have partnered to facilitate access to certain ViroPharma products through a named patient program (NPP). ViroPharma's NPP, developed and managed by Idis, will allow international healthcare professionals to prescribe certain products to individual patients until the time that approval is sought in local countries.

7 Dec 2010

Sequella files SQ109 IND for Phase 2 studies in H. pylori-related duodenal ulcers

Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of infectious diseases, announced it has successfully filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) to test SQ109 in patients suffering from H. pylori-related duodenal ulcers, and can now begin Phase 2 studies.

7 Dec 2010

Blocking quorum sensing would prevent bacteria from turning pathogenic

Bacteria are among the simplest organisms in nature, but many of them can still talk to each other, using a chemical "language" that is critical to the process of infection. Sending and receiving chemical signals allows bacteria to mind their own business when they are scarce and vulnerable, and then mount an attack after they become numerous enough to overwhelm the host's immune system.

7 Dec 2010

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide compounds against impetigo, Galderma has agreed to exercise its option for this indication.

6 Dec 2010

Research on ribosome could aid antibiotic development against MRSA infection

Theoretical biologists at Los Alamos National Laboratory have used a New Mexico supercomputer to aid an international research team in untangling another mystery related to ribosomes-those enigmatic jumbles of molecules that are the protein factories of living cells.

3 Dec 2010

St. Jude ICU honored with Beacon Award for Critical Care Excellence for second consecutive year

The Intensive Care Unit (ICU) at St. Jude Children's Research Hospital has been recognized for the second consecutive year with the Beacon Award for Critical Care Excellence given by the American Association of Critical-Care Nurses (AACN). In 2009, the St. Jude ICU became Tennessee's first ICU to win the honor.

2 Dec 2010

FDA approves CUBICIN 2-minute IV injection for MRSA skin infections, bacteremia

Cubist Pharmaceuticals, Inc. today announced that its currently-marketed antibiotic, CUBICIN (daptomycin for injection), has been approved by the U.S. Food & Drug Administration (FDA) for once-a-day dosing as a 2-minute intravenous (IV) injection.

2 Dec 2010

Anacor, UCSF and NYBC collaborate to discover drug therapies for river blindness

Anacor Pharmaceuticals, the University of California San Francisco (UCSF) Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center (NYBC) today announced the establishment of a research and development collaboration to discover new drug therapies for the treatment of river blindness (onchocerciasis), a parasitic disease that is the second leading cause of infectious blindness worldwide, and is most prevalent in Africa.

1 Dec 2010

Washington State Hospital Association makes public surgical infection rates

Today, the Washington State Hospital Association is releasing hospital-specific surgical infection rate data. This is the first time this information has been made public.

1 Dec 2010

Anacor completes initial public offering of common stock

Anacor Pharmaceuticals, Inc. today announced the completion of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share.

30 Nov 2010

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a long-term care or rehabilitation facility.

30 Nov 2010

Renhuang Pharmaceuticals changes name to China Botanic Pharmaceutical

China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the Company's Articles of Incorporation have been amended to effect the name change of the Company from its former name of Renhuang Pharmaceuticals.

29 Nov 2010

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces a successful meeting with the US Food and Drug Administration (FDA) to discuss the Company's clinical development of its Aganocide compound NVC-422, intended for use in the treatment of impetigo.

29 Nov 2010

Superantigens can disrupt immune system, can cause more illnesses

Superantigens, the toxins produced by staphylococcus bacteria, are more complex than previously believed, reveals a team of researchers from the University of Gothenburg in an article published today in the scientific journal Nature Communications. Their discovery shows that the body's immune system can cause more illnesses than realised.

29 Nov 2010